Considering HCC incidence is rapidly increasing worldwide and therapeutic choices are limited, here we consider the role of the PI3K/Akt/mTOR pathway in HCC, while it is a focus of current clinical practice and subject of intense investigation for future therapeutic development. The gene discussed is MTOR; the disease is hepatocellular carcinoma.